\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Dr. Stapleton has over 20 years of industry experience leading technical, quality and production operations in clinical and advertising biopharmaceutical companies.
SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Ray Stapleton, Ph. D. , as Chief Technology Officer (CTO), effective immediately. Dr. Stapleton joins Vaxart from Genocea, where he served as CTO and executive vice president, and is running to expand next-generation personalized immunotherapies in the form of vaccines and mobile therapies.
“Manufacturing is a vital component of vaccine development, and we are thrilled to have a CTO with the intensity and breadth of Ray’s professional delight to enroll in our leadership team,” said Andrei Floroiu, CEO of Vaxart. Ray will help us realize our vision of developing next-generation oral vaccines that promise how we fight infectious diseases globally.
“Vaxart’s pill-shaped vaccines have the potential to revolutionize the way vaccines are vaccinated globally and I am excited to be part of the team running to advance Vaxart’s production and core development programs,” said Dr. Stapleton. “I have spent my career working with the most advanced science and there is nothing more rewarding than the opportunity to improve human fitness on a large scale. “
Dr. Stapleton joined Genocea in January 2021, bringing more than 20 years of experience to the company, having led technical, quality and production operations in advertising and clinical phase biopharmaceutical companies.
Prior to that, he was president and chief operating officer of the American Type Culture Collection (ATCC), as well as a member of the board of directors of ATCC and ATCC Global. Prior to ATCC, Dr. Stapleton held leadership positions in production and technical operations. at Iovance Biotherapeutics, Inc. and Synthetic Biologics, Inc. after spending 15 years in positions of increasing responsibility within the Merck and Company production organization.
At Merck, Dr. Stapleton led a complex science, generation and engineering organization at a production site for Merck’s $5 billion annual vaccine business.
Dr. Stapleton holds a bachelor’s degree in biology from Mary Washington College in Fredericksburg, Virginia, and a doctorate. in microbial ecology from the University of Tennessee at Knoxville. He has been an examiner for a dozen clinical journals, co-author of 17 peer-reviewed manuscripts, and holds several patents.
About Vaxart Vaxart is a clinical-stage biogeneration company featuring a variety of recombinant oral vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered in pills that can be stored and shipped without refrigeration and eliminate the threat of needlestick injury. Vaxart believes its proprietary pill vaccine delivery platform is suitable for the delivery of recombinant vaccines, positioning the company to expand oral versions of recently announced vaccines and to design recombinant vaccines for new indications. Vaxart’s progression systems lately come with vaccines in pill form designed for coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a curative vaccine against human papillomavirus (HPV), Vaxart’s first indication of immuno-oncology. Vaxart has submitted extensive domestic and foreign patent programs covering its patented generation and creations for oral vaccination adenoviru ses and TLR3 agonists.
Note on Forward-Looking Statements This press release contains forward-looking statements that involve very wide risks and uncertainties. All statements, other than forward-looking statements of fact, included in this press release relating to Vaxart’s strategy, prospects, plans and objectives, the effects of preclinical and clinical trials, marketing agreements and licenses , as well as the ideals and expectations of management are prospective. statements. These forward-looking statements would possibly be accompanied by words such as “deserve”, “believe”, “may also just”, “potential”, “will”, “expect”, “anticipate”, “plan” and other terms. and situations of similar meaning. Examples of such statements include, but are not limited to, statements regarding Vaxart’s ability to expand and commercialize its product candidates, adding its vaccine booster products; Vaxart’s expectations regarding clinical effects and trial data; and Vaxart’s expectations regarding the efficacy of its product candidates. Vaxart may not achieve the plans, intentions, or expectations or projections disclosed in any forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual events or events may also differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various vital points may also cause actual effects or occasions to differ materially from forward-looking statements made through Vaxart.
See also the hazards described in the “Risk Factors” sections of Vaxart’s quarterly and annual reports filed with the SEC. Vaxart assumes no legal responsibility to update forward-looking statements, as required by law.
Contacts
Vaxart Media Relations:
Investor Relations:
marc herr
Andre Blazier
vaxart, inc.
FINN Partners
mherr@vaxart. com
IR@vaxart. com
(203) 517-8957
(646) 871-8486